[Treatment of arrhythmia in coronary patients and hypertensives with beta blockers and Depasan retard].
In the ambulatory of an internal specialist a number of patients suffering from angina pectoris or hypertonia together with arrhythmic troubles received an initial treatment with beta-blockers over a period of 21 days. In cases in which arrhythmia persisted after this initial period the treatment was continued for another 21 days with the addition of Depasan retard in function of a second medicament. This combined treatment in form of an open study was extended to a total number of 50 patients presenting ventricular extrasystolia in 45 cases and in 5 cases absolute arrhythmia in addition to the main disease. Treatment with Depasan retard showed good or satisfactory results in 39 out of 45 patients suffering from ventricular extrasystoles, whilst no effect could be obtained in the 5 cases with absolute arrhythmia. No signs of incompatibility or unwanted interactions were observed in the course of this open study. Based on these results it can be concluded that Depasan retard should be recommended in those cases where on account of persistent arrhythmical troubles and especially extrasystoles, during a treatment with beta-blockers in patients suffering from angina pectoris or hypertonia, and additional treatment with anti-arrhythmical medicaments appears to be indicated.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D001281:Atrial Fibrillation / Q000188:drug therapy; D005117:Cardiac Complexes, Premature / Q000188:drug therapy; D003327:Coronary Disease / Q000150:complications*; D003692:Delayed-Action Preparations; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications*; D008297:Male; D008875:Middle Aged; D013034:Sparteine / Q000627:therapeutic use*
D000319:Adrenergic beta-Antagonists; D003692:Delayed-Action Preparations; D013034:Sparteine
Behandlung von Herzrhythmusstörungen bei Koronarpatienten und Hypertonikern mit Beta-Blockern und Depasan retard.